What the FDA Actually Did With Peptides Last Week

If your feed suddenly filled up with "FDA legalizes BPC-157!!" headlines, take a breath — that's not quite what happened.

On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) met at the agency's White Oak campus (Docket FDA-2025-N-6895) to vote on whether seven popular research peptides should be added to the Section 503A Bulk Drug Substances List — the list that determines what compounding pharmacies are allowed to legally prepare.

The seven peptides on the table: BPC-157, TB-500, KPV, MOTS-c (discussed July 23), and Emideltide (DSIP), Semax, Epitalon (discussed July 24).

The Votes

A note on sourcing: FDA hasn't posted its official meeting transcript or archived webcast yet, so the tallies below come from press and industry attendees who were in the room, not from an FDA-published document. Multiple independent outlets report the same numbers, but treat these as reported-pending-official-confirmation rather than final.

The committee reportedly recommended six of the seven:

• BPC-157 — 8–6–1
• TB-500 — 8–6–1
• KPV — 8–6–1
• MOTS-c — 7–5
• Semax — 8–5
• Epitalon — 7–5
• Emideltide (DSIP) — rejected, 6–7 with one abstention

The FDA's own staff scientists had recommended voting against all seven, citing thin safety and efficacy data. The panel reportedly overruled them on six. Emideltide — pitched for insomnia and opioid-withdrawal use — was the one exception; the panel wasn't convinced there was enough data to back that up.

What This Does NOT Mean

• Nothing is legal or approved yet. A PCAC recommendation is advisory only — not binding on the FDA.
• The FDA still has to run this through formal rulemaking, which realistically stretches into 2027.
• None of these peptides have FDA approval for human use, and none have completed real human clinical trials.
• Another peptide-focused FDA meeting is expected before February 2027 — this isn't the end of the process.

Why People Are Paying Attention

This is notable mainly because it's reportedly the first time an FDA advisory panel has voted to loosen restrictions on unapproved peptides rather than tighten them. The docket drew roughly 1,860 public comments before closing on July 22 — a sign of how much interest is riding on the outcome.

Bottom Line

The FDA didn't legalize anything last week. A panel of outside experts reportedly told the FDA "these six look reasonable enough to consider," the FDA's own scientists disagreed, and now the slow part — actual rulemaking — starts. We'll update this post with exact vote counts once FDA posts its official transcript.

---

Sources:

• FDA meeting calendar — July 23-24, 2026 PCAC
• Federal Register meeting notice
• FDA 2026 PCAC meeting materials
• FDA briefing document
• Mintz — what the vote does and doesn't do
• Medical Daily — final votes, Emideltide rejected